
Delcath Systems (DCTH) Stock Forecast & Price Target
Delcath Systems (DCTH) Analyst Ratings
Bulls say
Delcath Systems Inc. has reported a remarkable 140% growth in Hepzato procedure volume in 2025, indicating rising physician adoption and increased utilization of their treatment options. The company's year-end cash balance reached $91.0 million, showing a slight yet positive increase from the previous quarter, highlighting operational efficiency and financial stability. Furthermore, with plans for salesforce expansion in 2026 and expectations for the upcoming CHOPIN trial data to enhance clinical adoption, the outlook remains positive as these initiatives are anticipated to bolster Hepzato's market presence and drive revenue growth.
Bears say
Delcath Systems Inc. has revised its full-year revenue expectations down to $83 million-$85 million, significantly lower than the previous range of $93 million-$96 million, primarily due to a slowdown in new site activations and decreased patient starts attributed to summer seasonality and competitive clinical trials. Additionally, the company is facing declining average revenue per kit as a result of the Medicaid National Drug Rebate Agreement, with anticipated discounts impacting half of their patient base at approximately 23%. Lastly, Delcath Systems is currently cash flow negative, raising concerns regarding its ability to sustain operations and achieve forecasted revenue levels in the future.
This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.
Delcath Systems (DCTH) Analyst Forecast & Price Prediction
Start investing in Delcath Systems (DCTH)
Order type
Buy in
Order amount
Est. shares
0 shares